Nishadil
Nishadil Ads Nishadil Astrology Nishadil Developers Nishadil Domains Nishadil Drive Nishadil Finance Nishadil Pay Nishadil Weather Nishdil Calendar Rewards
Signup Signin
Washington | 19°C (overcast clouds)
Topic Feed

Regn

Showing the latest stories and updates for this topic.
Nasdaq's Remarkable Reversal: How Chipmakers Sparked a Green Comeback

Nasdaq's Remarkable Reversal: How Chipmakers Sparked a Green Comeback
Electromed: A Closer Look at What Lies Beyond the Immediate Horizon

Electromed: A Closer Look at What Lies Beyond the Immediate Horizon
Corvus Pharmaceuticals Takes Key Step Forward with Lead Eczema Drug

Corvus Pharmaceuticals Takes Key Step Forward with Lead Eczema Drug
Regeneron's Remarkable Resurgence: Charting the Course of a Biotech Comeback

Regeneron's Remarkable Resurgence: Charting the Course of a Biotech Comeback
CRISPR Therapeutics: Beyond the Hype, A Foundational Investment in Gene Editing's Future

CRISPR Therapeutics: Beyond the Hype, A Foundational Investment in Gene Editing's Future
Regeneron and Tessera Forge Potent Alliance for Next-Generation Gene Editing Therapies

Regeneron and Tessera Forge Potent Alliance for Next-Generation Gene Editing Therapies
A Bold Bet on the Future: Regeneron's $150M Investment in Gene Writing

A Bold Bet on the Future: Regeneron's $150M Investment in Gene Writing
A Fresh Look at Regeneron: Why Analysts Are Seeing Significant Upside

A Fresh Look at Regeneron: Why Analysts Are Seeing Significant Upside
Regeneron's Remarkable Q3: A Dupixent-Driven Triumph That Reaffirms Biotech's Pulse

Regeneron's Remarkable Q3: A Dupixent-Driven Triumph That Reaffirms Biotech's Pulse
The Anticipation Builds: Kymera's Big Bet on Better Skin Could Be a Game-Changer

The Anticipation Builds: Kymera's Big Bet on Better Skin Could Be a Game-Changer
The Intelligent Pivot: How Savvy Acquisitions Are Forging a New Path to Profitability

The Intelligent Pivot: How Savvy Acquisitions Are Forging a New Path to Profitability
The Biotech Bonanza: Unearthing Tomorrow's Investment Gems in a Volatile Market

The Biotech Bonanza: Unearthing Tomorrow's Investment Gems in a Volatile Market
The Great Pharma Debate: Which Giant Will Dominate Your Portfolio?

The Great Pharma Debate: Which Giant Will Dominate Your Portfolio?
Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs

Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs
Regeneron's Evkeeza Achieves Landmark FDA Approval, Extending Life-Saving Treatment to Youngest HoFH Patients

Regeneron's Evkeeza Achieves Landmark FDA Approval, Extending Life-Saving Treatment to Youngest HoFH Patients
Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule

Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule
Regeneron's Growth Horizon: Beyond the Core, Towards New Frontiers

Regeneron's Growth Horizon: Beyond the Core, Towards New Frontiers
A Beacon of Hope: Regeneron's Pozelimab Shines in Ultra-Rare Genetic Disorder Study

A Beacon of Hope: Regeneron's Pozelimab Shines in Ultra-Rare Genetic Disorder Study
A New Chapter for Ophthalmology: Regeneron and Sandoz Resolve Landmark Eylea Patent Battle

A New Chapter for Ophthalmology: Regeneron and Sandoz Resolve Landmark Eylea Patent Battle
First RSV shots, groundbreaking gene therapy among 2024 drugs to watch

First RSV shots, groundbreaking gene therapy among 2024 drugs to watch
RBC ups Regeneron to outperform; cites Eylea patent win, Dupi sales

RBC ups Regeneron to outperform; cites Eylea patent win, Dupi sales
Load more..